
    
      Approximately 200 patients who are planning to undergo or have undergone CXL for the
      treatment of corneal ectasia following refractive surgery in one or both eyes according to
      the prescribing information in the Photrexa Viscous and Photrexa Package Insert could be
      enrolled. Patients will be followed for safety and effectiveness at Months 3, 6, 12, 24 and
      36 following cross-linking treatment.
    
  